Adia Nutrition Inc. Announces IRB Approval from BeyondBound for Adia Med's Autism Clinical Study
TMX Newsfile·2025-12-15 15:30
Winter Park, Florida--(Newsfile Corp. - December 15, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med subsidiary, today announced that the independent Institutional Review Board (IRB) BeyondBound has approved the company's patent-pending clinical study protocol focused on Autism Spectrum Disorder (ASD).IRB Approval EmailTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/278050_adia_irb_approved_screenshot.jp ...